Attenuation of Bone Mineral Density Decline During Anemia Treatment With Methenolone Acetate in Myelodysplastic Syndrome
© The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society..
In an aging society, addressing the risks and management of osteoporotic fractures is critical to reduce mortality. Similarly, the morbidity of chronic kidney disease and myelodysplastic syndrome increases with aging. The association between chronic kidney disease and fractures is well understood; however, recent reports have indicated an increased risk of incident osteoporosis in patients with prevalent myelodysplastic syndrome. In this case report, we present an older man with stage 4 chronic kidney disease complicated by myelodysplastic syndrome and progressive decline in bone mineral density. He was treated with methenolone acetate and darbepoetin for anemia caused by myelodysplastic syndrome. During anemia treatment, the decline in bone mineral density was attenuated overtime. The case findings suggest the potential association between the use of methenolone acetate as a synthetic anabolic steroid and attenuated decline in bone mineral density.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:2 |
|---|---|
| Enthalten in: |
JCEM case reports - 2(2024), 4 vom: 30. Apr., Seite luae055 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ushimaru, Shu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1,25-dihydroxyvitamin D3 |
|---|
| Anmerkungen: |
Date Revised 25.04.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1210/jcemcr/luae055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371126614 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371126614 | ||
| 003 | DE-627 | ||
| 005 | 20240425234828.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240416s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1210/jcemcr/luae055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM371126614 | ||
| 035 | |a (NLM)38623532 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ushimaru, Shu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Attenuation of Bone Mineral Density Decline During Anemia Treatment With Methenolone Acetate in Myelodysplastic Syndrome |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2024. Published by Oxford University Press on behalf of the Endocrine Society. | ||
| 520 | |a In an aging society, addressing the risks and management of osteoporotic fractures is critical to reduce mortality. Similarly, the morbidity of chronic kidney disease and myelodysplastic syndrome increases with aging. The association between chronic kidney disease and fractures is well understood; however, recent reports have indicated an increased risk of incident osteoporosis in patients with prevalent myelodysplastic syndrome. In this case report, we present an older man with stage 4 chronic kidney disease complicated by myelodysplastic syndrome and progressive decline in bone mineral density. He was treated with methenolone acetate and darbepoetin for anemia caused by myelodysplastic syndrome. During anemia treatment, the decline in bone mineral density was attenuated overtime. The case findings suggest the potential association between the use of methenolone acetate as a synthetic anabolic steroid and attenuated decline in bone mineral density | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a 1,25-dihydroxyvitamin D3 | |
| 650 | 4 | |a anemia treatment | |
| 650 | 4 | |a bone mineral density | |
| 650 | 4 | |a bone turnover markers | |
| 650 | 4 | |a methenolone acetate | |
| 700 | 1 | |a Sumi, Hirofumi |e verfasserin |4 aut | |
| 700 | 1 | |a Aso, Mea |e verfasserin |4 aut | |
| 700 | 1 | |a Fujishima, Rie |e verfasserin |4 aut | |
| 700 | 1 | |a Shiizaki, Kazuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Tominaga, Naoto |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JCEM case reports |d 2023 |g 2(2024), 4 vom: 30. Apr., Seite luae055 |w (DE-627)NLM357254589 |x 2755-1520 |7 nnns |
| 773 | 1 | 8 | |g volume:2 |g year:2024 |g number:4 |g day:30 |g month:04 |g pages:luae055 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1210/jcemcr/luae055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 2 |j 2024 |e 4 |b 30 |c 04 |h luae055 | ||